Table 1.
Baseline characteristics, cardiovascular risk factors, and clinical history of the TURKMI population
| Total n=1930 | NSTEMI n=1195 | STEMI n=735 | P value* | |
|---|---|---|---|---|
| Age, years (median, Q1-Q3) | 62 (53-71) | 63 (54-72) | 60 (51-70) | <0.001 |
| Age, year (mean±SD) | 62±13.2 | 63±12.7 | 60.4±13.8 | |
| Female patients, n (%) | 504 (26.1) | 343 (28.7) | 161 (21.9) | <0.001 |
| Body mass index (kg/m2) (median, Q1-Q3) | 27.4 (25-30.8) | 27.7 (25.2-31.1) | 27.1 (24.78-30.1) | 0.071 |
| Risk factors | ||||
| Hypertension, n (%) | ||||
| Based on patient’s self-report | 955 (49.5) | 672 (56.2) | 283 (38.5) | <0.001 |
| Dyslipidemia, n (%) | ||||
| Based on patient’s self-report | 233 (12.1) | 161 (13.5) | 72 (9.8) | 0.016 |
| Hypercholesterolemia (LDL ≥130 mg/dL or total | 875 (60.2) | 588 (64.3) | 287 (53.1) | <0.001 |
| cholesterol ≥200 mg/d or use of LDL-lowering agents)** | ||||
| Low HDL cholesterol (men: <40 mg/dL; women: <50 mg/dL) | 837 (56.6) | 523 (56.5) | 314 (56.8) | 0.928 |
| Elevated triglycerides (≥150 mg/dL) | 612 (43.7) | 418 (47.6) | 194 (37.2) | <0.001 |
| Dyslipidemia (Presence of any of the above criteria), n (%) | 1333 (88.3) | 850 (89.7) | 483 (86.1) | 0.037 |
| Diabetes, n (%) | ||||
| Based on patient’s self-report | 654 (33.9) | 448 (37.5) | 206 (28) | <0.001 |
| Based on patient’s self-report and/or use of anti-diabetic agents | 691 (37.9) | 472 (41.6) | 219 (31.9) | <0.001 |
| Obesity, n (%) | ||||
| Based on patient’s self-report | 112 (5.8) | 66 (5.5) | 46 (6.3) | 0.502 |
| Body mass index ≥30 kg/m2 | 497 (28.7) | 326 (30.5) | 171 (25.8) | 0.034 |
| Smoking, n (%) | 942 (48.8) | 529 (44.3) | 413 (56.2) | <0.001 |
| Family history of premature CVD, n (%) | 188 (9.7) | 109 (9.1) | 79 (10.7) | 0.242 |
| Alcohol, n (%) | 46 (2.4) | 24 (2) | 22 (3) | 0.168 |
| History of CVD, n (%) | ||||
| Coronary involvement (MI and/or CABG and/or PCI) | 550 (28.5) | 418 (35) | 132 (18) | <0.001 |
| Myocardial infarction | 262 (13.6) | 190 (15.9) | 72 (9.8) | <0.001 |
| Percutaneous coronary intervention | 339 (17.6) | 258 (21.6) | 81 (11) | <0.001 |
| Coronary bypass grafting | 165 (8.5) | 139 (11.6) | 26 (3.5) | <0.001 |
| Transient ischemic attack or stroke | 29 (1.5) | 13 (1.1) | 16 (2.2) | 0.056 |
| Peripheral arterial disease | 17 (0.9) | 10 (0.8) | 7 (1) | 0.792 |
| Heart failure | 45 (2.3) | 35 (2.9) | 10 (1.4) | 0.027 |
| Atrial fibrillation | 23 (1.2) | 16 (1.3) | 7 (1) | 0.447 |
| Valve surgery | 5 (0.3) | 5 (0.4) | 0 (0) | 0.164 |
| Pacemaker/intracardiac defibrillator | 7 (0.4) | 5 (0.4) | 2 (0.3) | 0.715 |
| Other | 25 (1.3) | 19 (1.6) | 6 (0.8) | 0.144 |
| Concomitant disease, n (%) | ||||
| Cancer | 54 (2.8) | 30 (2.5) | 24 (3.3) | 0.329 |
| Thyroid disease | 50 (2.6) | 30 (2.5) | 20 (2.7) | 0.777 |
| Renal failure | 103 (5.3) | 72 (6.0) | 31 (4.2) | 0.086 |
| Chronic obstructive lung disease | 95 (4.9) | 68 (5.7) | 27 (3.7) | 0.047 |
| Asthma | 35 (1.8) | 24 (2) | 11 (1.5) | 0.413 |
| History of bleeding | 10 (0.5) | 7 (0.6) | 3 (0.4) | 0.750 |
| Connective tissue disease | 9 (0.5) | 6 (0.5) | 3 (0.4) | 1.000 |
| Other | 142 (7.4) | 93 (7.8) | 49 (6.7) | 0.362 |
*
P value denotes the comparison of STEMI and NSTEMI.
**
As there were missing values in both statin use and lipid levels, analysis was conducted by excluding the missing values.
CABG - coronary artery bypass grafting; CVD - cardiovascular disease; HDL - high density lipoproteins; LDL - low density lipoproteins; MI - myocardial infarction; NSTEMI - non-ST elevation MI; PCI - percutaneous coronary intervention; SD - standard deviation; STEMI - ST elevation MI